Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dodick

Showing results (491-500 of 620) with videos related to

Pageof 62
Sort By:
JAMA|May 26, 2018
Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical TrialDavid W Dodick, Stephen D Silberstein, Marcelo E Bigal, et al.
Nature Reviews. Disease Primers|January 14, 2022
MigraineMichel D Ferrari, Peter J Goadsby, Rami Burstein, et al.
Lancet (London, England)|November 18, 2023
Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USADavid W Dodick, Peter J Goadsby, Todd J Schwedt, et al.
The Lancet. Neurology|October 4, 2015
Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b studyMarcelo E Bigal, David W Dodick, Alan M Rapoport, et al.
Cephalalgia : an International Journal of Headache|June 1, 2019
Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraineMessoud Ashina, Peter J Goadsby, Uwe Reuter, et al.
Nature Medicine|May 12, 2025
Ubrogepant for the treatment of migraine prodromal symptoms: an exploratory analysis from the randomized phase 3 PRODROME trialPeter J Goadsby, Jessica Ailani, David W Dodick, et al.
Cephalalgia : an International Journal of Headache|November 2, 2020
Characterization and preclinical evaluation of a protease activated receptor 2 (PAR2) monoclonal antibody as a preventive therapy for migraineCaroline M Kopruszinski, Peter Thornton, Joanne Arnold, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|March 29, 2014
Association of ischemic stroke, hormone therapy, and right to left shunt in postmenopausal womenNancy C Greep, David S Liebeskind, Rubine Gevorgyan, et al.
Headache|June 14, 2023
Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysisStewart J Tepper, Richard B Lipton, Stephen D Silberstein, et al.
Headache|September 30, 2021
Risk of hypertension in erenumab-treated patients with migraine: Analyses of clinical trial and postmarketing dataDavid W Dodick, Stewart J Tepper, Jessica Ailani, et al.
Pageof 62

Showing results (491-500 of 620) with videos related to

Sort By:
Pageof 62
JAMA|May 26, 2018
Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical TrialDavid W Dodick, Stephen D Silberstein, Marcelo E Bigal, et al.
Nature Reviews. Disease Primers|January 14, 2022
MigraineMichel D Ferrari, Peter J Goadsby, Rami Burstein, et al.
Lancet (London, England)|November 18, 2023
Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USADavid W Dodick, Peter J Goadsby, Todd J Schwedt, et al.
The Lancet. Neurology|October 4, 2015
Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b studyMarcelo E Bigal, David W Dodick, Alan M Rapoport, et al.
Cephalalgia : an International Journal of Headache|June 1, 2019
Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraineMessoud Ashina, Peter J Goadsby, Uwe Reuter, et al.
Nature Medicine|May 12, 2025
Ubrogepant for the treatment of migraine prodromal symptoms: an exploratory analysis from the randomized phase 3 PRODROME trialPeter J Goadsby, Jessica Ailani, David W Dodick, et al.
Cephalalgia : an International Journal of Headache|November 2, 2020
Characterization and preclinical evaluation of a protease activated receptor 2 (PAR2) monoclonal antibody as a preventive therapy for migraineCaroline M Kopruszinski, Peter Thornton, Joanne Arnold, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|March 29, 2014
Association of ischemic stroke, hormone therapy, and right to left shunt in postmenopausal womenNancy C Greep, David S Liebeskind, Rubine Gevorgyan, et al.
Headache|June 14, 2023
Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysisStewart J Tepper, Richard B Lipton, Stephen D Silberstein, et al.
Headache|September 30, 2021
Risk of hypertension in erenumab-treated patients with migraine: Analyses of clinical trial and postmarketing dataDavid W Dodick, Stewart J Tepper, Jessica Ailani, et al.
Pageof 62